Ten-Year Trends of Clinicopathologic Features and Surgical Treatment of Lung Cancer in China.
Lung cancer has changed significantly during the past two decades in its epidemiology and treatment. We conducted a retrospective analysis using data from seven major areas of China over ten years to evaluate clinicopathologic and surgical treatment trends of lung cancer in China during the past decade METHODS: Data from 7184 primary lung cancer patients treated between 2005 and 2014 in eight provinces over China were retrospectively collected. Their clinicopathologic features and surgical treatment information were recorded. Simple linear regression models and Cochran-Armitage Trend test were used to assess the temporal trends. The proportion of female (from 57.4 to 59.6, p<0.001) and nonsmoking (from 37.1% to 48.9%, p<0.001) patients and of patients with family history of malignant tumors (from 7.0% to 11.5%, p<0.001) increased significantly. The percentage of adenocarcinoma increased significantly (from 36.4% to 53.5%, p<0.001) with a decrease in squamous cell carcinoma (from 45.4% to 34.4%, p<0.001). After 2008, the application of minimally invasive surgery significantly increased in China (from 2.4% in 2008 to 34.4% in 2014, p<0.001) with a decline in conversion rate (from 14.3% in 2008 to 4.8% in 2014, p=0.146) and an increase in the proportion of systematic mediastinal lymph node dissection (from 50.0% in 2008 to 84.1% in 2014, p=0.001). Our study investigated a recent ten-year trend in the clinicopathologic features and surgical treatment of lung cancer in China and found significant important changes. These findings provide important information and evidence for the future control of the disease in China.